Newsroom | 39086 results
Sorted by: Latest
-
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies announces closing of $4M private placement offering....
-
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update...
-
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth’s technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company’s PIKTOR clinical development progr...
-
Innate Pharma Announces Conference Call and Webcast
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast...
-
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS...
-
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un...
-
Saptalis Pharmaceuticals and Coformer AI Partner to Develop Next-Generation Drug Formulations for Neurology and Oncology
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals and Coformer AI today announced a strategic research partnership to develop next-generation pharmaceutical formulations that address some of the industry's most persistent challenges, including poor solubility, low bioavailability, and dose-limiting toxicity. The collaboration will initially focus on neurology and oncology programs where improved formulation performance may translate into better therapeutic outcomes. The partnership bri...
-
AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical named a 2026 Prix Galien USA "Best Startup" nominee for its personalized cancer immunotherapy platform....
-
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies announces pricing of $4M private placement offering....
-
Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) announced a strategic collaboration with Merck to utilize SCRI’s Accelero™ delivery model....
